Verlyn G Schaefer is a notable inventor based in Libertyville, IL (US). She has made significant contributions to the field of biotechnology, particularly in the development of expression systems for hepatitis C virus proteins. With a total of 2 patents, her work has the potential to advance the understanding and treatment of hepatitis C.

Latest Patents

One of her latest patents is focused on the Hepatitis C virus second envelope (HCV-E2) glycoprotein expression system. This invention provides a novel mammalian expression system capable of generating high levels of expressed hepatitis C virus (HCV) proteins, which have previously proved difficult to express due to their non-secretory properties. The invention includes a plasmid for the expression of the HCV second envelope protein (E2), designated p577. This plasmid encodes a recombinant protein comprising the immunoglobulin signal peptide and amino acids 388-664 of the HCV E2 glycoprotein. This unique expression system produces high levels of HCV proteins that are properly processed, glycosylated, and folded. Another patent involves DNA encoding a human erythropoietin analog, further showcasing her innovative capabilities.

Career Highlights

Verlyn G Schaefer is associated with Abbott Laboratories Corporation, a leading company in the healthcare sector. Her work at Abbott has allowed her to focus on groundbreaking research that addresses critical health issues.

Collaborations

Throughout her career, she has collaborated with esteemed colleagues such as Gregory F Okasinski and Peter J DeVries. These collaborations have contributed to the advancement of her research and the successful development of her patents.

Conclusion

Verlyn G Schaefer's contributions to the field of biotechnology, particularly in hepatitis C research, highlight her innovative spirit and dedication to improving healthcare solutions. Her patents represent significant advancements that could lead to better treatment options for patients.